Thursday 29 September 2022

PROGRAMME DAY 4

08:30 - 09:00
Plenary Session 4 | Main Auditorium

Advances in our Understanding of SARS-CoV-2
Yoshihiro Kawakura, University of Wisconsin-Madison, USA
Can Human Challenge Models Accelerate Respiratory Virus Vaccine Development?
Kathleen Neuzil, University of Maryland, USA
The Perils of Predicting Epidemics: How Untangling Transmission Drivers Can Improve Forecasting
Adam Kucharski, London School of Hygiene & Tropical Medicine, UK

09:00 - 09:30
Tea break | Hall 1

09:30 - 10:00
0:20 - 10:30
Virology & Pathogenesis
Clinical Sciences & Vaccinology
Public Health & Policy

10:30 - 12:00
Zoonotic Influenza
Influenza & COVID-19 - Human Challenge Models
Vaccine Effectiveness for Influenza

Chair(s) TBC
Session Speaker: Nicola Lewis
Francis Crick Institute, UK

Chair(s) TBC
Session Speaker: Christopher Chiu
Imperial College London, UK

Chair(s) TBC
Session Speaker: Nancy Leung
University of Hong Kong, Hong Kong

11:00 - 11:12
Influenza A (H1n1) detection in faecal samples from Adelie (Pygoscelis adeliae) and chinstrap (Pygoscelis antarcticus) penguins, Penguin Island, Antarctic [AOXI0210]
Maria Ogrozniewska, Oswaldo Cruz Foundation, Brazil

11:12 - 11:24
Influenza, COVID-19, RSV and H1N1: translating efficacy testing of vaccine and drugs from human challenge models to the field [AOXI0668]
Alex Mann, IVIVO, UK

11:24 - 11:36
Mapping the molecular basis of antigenic evolution of H5 highly pathogenic avian influenza viruses to support the design of broadly reactive vaccines [AOXI0648]
Mathilde Richard, Erasmus MC, Netherlands

11:36 - 11:48
Cross-species spill-over potential of the H5N2-like bat influenza virus [AOXI0075]
Ghazal Kayali, Human Link DMCC, United Arab Emirates

11:48 - 12:00
Rapid surge of the H3pdmN1av reassortant in Danish swine and its zoonotic potential [AOXI0099]
Pia Ryt-Hansen, University of Copenhagen, Denmark

12:00 - 13:00
Lunch / sponsored symposium | Hall 1

SARS-COV-2: Novel Treatment and Prevention Strategies
Surveillance for Influenza including Joint Surveillance and Impact of COVID-19 on other Respiratory Virus Diseases
Vaccine Effectiveness for COVID-19 and Implications for Influenza

Chair(s) tbc
Session Speaker: Laura Martin-Sancho
Scripps Research Institute, USA,

Chair(s) tbc
Session Speaker: Sibongile Walaza
NCID, South Africa

Chair(s) tbc
Session Speaker: Joe Lewnard
University of California, Berkeley, USA

13:30 - 13:42
CYP19A1 mediated sex hormone metabolism promotes severe SARS-CoV-2 disease outcome in males [AOXI0241]
Sebastian Beck, Leibniz Institute of Virology, Germany

13:42 - 13:54
OVX33, T-cell based vaccine targeting the Nucleoplasid provides broad-spectrum protection against SARS-CoV-2 Voe in hamster challenge model [AOXI0230]
Alexandre Le Vert, Oviva, France

13:54 - 14:06
Development and application of a next-generation single-dose mucosal COVID-19 vaccine [AOXI0426]
Michael D’Agostino, McMaster University, Canada

14:06 - 14:18
Efficacy and safety of SAB-162, a novel anti-Type A and B influenza immunotherapeutic: a Phase 2a, randomized, double blind trial in H1N1 challenged adults [AOXI0452]
Thomas Luke, SAB Biotherapeutics, Inc, United States

14:18 - 14:30
How human challenge studies reveal vaccine efficacy and mode of action [AOXI0665]
Fumimari Miyano, National Institute for Public Health and the Environment (RIVM), Netherlands

14:30 - 14:42
Influenza virus dynamics in uncomplicated infection: impact of age and vaccination [AOXI0631]
Nicolas Noulis, IVIVO, UK

14:42 - 14:54
Impact of COVID-19 on influenza surveillance during 2020 in Ghana [AOXI0177]
Yaw Awuku-Larbi, Noguchi Memorial Institute for Medical Research, Ghana

14:54 - 15:06
Effectiveness of Influenza Vaccination During Pregnancy On Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada [AOXI0131]
Deshayne Fall, Children’s Hospital of Eastern Ontario, Canada

15:06 - 15:18
Other Respiratory Viral diseases in Pune western part of India [AOXI0254]
Varsha Potdar, National Institute of Virology Pune, India

15:18 - 15:30
AFRO-MoVE: African network to monitor vaccine effectiveness for COVID-19 and other respiratory pathogens [AOXI0427]
Celine Gurry, EpiConcept, France

15:30 - 15:42
Effectiveness of Influenza vaccination on Influenza A(H3N2) vaccine strain mismatch with the vaccine strain [AOXI0633]
Chelsea Hansen, Fogarty International Center, USA

15:42 - 15:54
Atypical seasonality of Influenza A(H3N2) in Brazil 2021-2022 and mismatch with the vaccine strain [AOXI0630]
Patricia Cristina Renesto, Fiocruz, Brazil

15:54 - 16:06
Surveillance of Influenza and SARS CoV2 and Impact of COVID-19 on influenza surveillance platform to monitor SARS-CoV-2: findings from its and Researcher-based influenza sentinel surveillance during first two years of COVID-19 in Bangladesh [AOXI0120]
Kathleen Neuzil, University of Maryland, USA

16:06 - 16:18
Using serological data to identify cryptical influenza infections and effect on vaccine responses [AOXI0121]
Brendan Flannery, Centers for Disease Control and Prevention, USA

16:18 - 16:30
Utilization of influenza surveillance platform to monitor SARS-CoV-2: findings from its and Researcher-based influenza sentinel surveillance during first two years of COVID-19 in Bangladesh [AOXI0123]
David Hodgson, London School of Hygiene and Tropical Medicine, UK

16:30 - 16:42
Vaccine effectiveness against influenza A and A(H3N2): Results from the 2021-22 season European I-MOVE primary care multicentre study [AOXI0036]
Esther Kissling, EpiConcept, France

16:42 - 16:54
Leveraging influenza vaccine effective networks for COVID-19 vaccine effectiveness studies [AOXI0135]
Kaya Lee, Marshfield Clinic Research Institute, USA

16:54 - 17:06
AFRO-MoVE: African network to monitor vaccine effectiveness for COVID-19 and other respiratory pathogens [AOXI0427]
Julia Rogers, University of Washington, USA

17:06 - 17:18
Leveraging Influenza vaccine effective networks for COVID-19 vaccine effectiveness studies [AOXI0135]
Brendan Flannery, Centers for Disease Control and Prevention, USA

17:18 - 17:30
Vaccine Effectiveness against Influenza and SARS-CoV-2 in Regions with Variable Influenza Activity [AOXI0127]
Chelsea Hansen, Fogarty International Center, USA

17:30 - 17:42
Leveraging influenza vaccine effective networks for COVID-19 vaccine effectiveness studies [AOXI0135]
Brendan Flannery, Centers for Disease Control and Prevention, USA

17:42 - 17:54
Monitoring COVID-19 vaccine effectiveness against symptomatic infection with variants of concern through home-based testing in King County, Washington [AOXI0228]
Brendan Flannery, Centers for Disease Control and Prevention, USA

17:54 - 18:06
Leveraging influenza vaccine effective networks for COVID-19 vaccine effectiveness studies [AOXI0135]
Brendan Flannery, Centers for Disease Control and Prevention, USA

18:06 - 18:18
Leveraging influenza vaccine effective networks for COVID-19 vaccine effectiveness studies [AOXI0135]
Brendan Flannery, Centers for Disease Control and Prevention, USA

18:18 - 18:30
Leveraging influenza vaccine effective networks for COVID-19 vaccine effectiveness studies [AOXI0135]
Brendan Flannery, Centers for Disease Control and Prevention, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:06 - 14:18</td>
<td>CLAROMERS: Synthetic oligomer mimics of antimicrobial peptides for treatment and prevention of SARS-CoV-2 and other respiratory viruses [AOX0472]</td>
<td>Kent Kirshenbaum, New York University / Maxwell Biosciences, USA</td>
<td>Main Auditorium</td>
</tr>
<tr>
<td>14:06-14:12</td>
<td>Late influenza A(H3N2) season after relaxation of COVID-19 restrictions driven by the 7-14 years old [AOX0227]</td>
<td>Hanne-Dorthe Endberg, Statens Seruminstitut, Denmark</td>
<td>Main Auditorium</td>
</tr>
<tr>
<td>14:12-14:18</td>
<td>Increased severity of influenza-related hospitalizations in resource-limited settings: Results from the Global Influenza Hospital Surveillance Network [AOX0160]</td>
<td>Kent Kirshenbaum, New York University / Maxwell Biosciences, USA</td>
<td>Main Auditorium</td>
</tr>
<tr>
<td>14:18-14:24</td>
<td>Homologous and heterologous boosting with third-dose BNT162b2 and CoronaVac: a randomized trial (Cobovax study) [AOX0164]</td>
<td>Nancy Hua Lan Leung, University of Hong Kong, Hong Kong</td>
<td>Main Auditorium</td>
</tr>
<tr>
<td>14:24-14:30</td>
<td>Increased severity of influenza-related hospitalizations in resource-limited settings: Results from the Global Influenza Hospital Surveillance Network [AOX0160]</td>
<td>Kent Kirshenbaum, New York University / Maxwell Biosciences, USA</td>
<td>Main Auditorium</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td>Tea break</td>
<td>location tbc</td>
<td>Main Auditorium</td>
</tr>
<tr>
<td>15:05 - 15:40</td>
<td>Closing Keynote Address</td>
<td>Influenza Research in the Post-COVID Era</td>
<td>Main Auditorium</td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td>Award Presentations &amp; Closing Remarks</td>
<td></td>
<td>Main Auditorium</td>
</tr>
</tbody>
</table>